Nuvation Bio (Nuvation Bio) Pre-Tax Income : $-75.80 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Nuvation Bio's pretax income for the three months ended in Dec. 2023 was $-13.79 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-75.80 Mil. Nuvation Bio's pretax margin was %.

Nuvation Bio Pre-Tax Income Historical Data

The historical data trend for Nuvation Bio's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Pre-Tax Income Chart

Nuvation Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

-41.66

-86.85

-104.20

-75.80

Nuvation Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial											-20.85	-21.73	-20.64	-19.65	-13.79

Competitive Comparison of Nuvation Bio's Pre-Tax Income

For the Biotechnology subindustry, Nuvation Bio's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuvation Bio's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvation Bio's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Nuvation Bio's Pre-Tax Income falls into.

Nuvation Bio Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Nuvation Bio's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-99.822	+	-0.591	+	0	+	24.611	+	-1.4210854715202E-14
	=	-75.80

Nuvation Bio's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-20.831	+	0.021	+	0	+	7.023	+	-1.7763568394003E-15
	=	-13.79

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-75.80 Mil.

Nuvation Bio (NYSE:NUVB.WS) Pre-Tax Income Explanation

Nuvation Bio's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-13.787	/	0
	=	%

Nuvation Bio Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvation Bio (Nuvation Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

NUVB:USA

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).